Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asger Lund

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Danish Medical Journal|April 8, 2017
On the role of the gut in diabetic hyperglucagonaemiaAsger Lund
Diabetes Research and Clinical Practice|June 27, 2018
Extrapancreatic glucagon: Present statusAsger Lund, Filip K Knop
Current Medical Research and Opinion|April 3, 2012
Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylureaAsger Lund, Filip K Knop
European Journal of Internal Medicine|April 4, 2014
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similaritiesAsger Lund, Filip K Knop, Tina Vilsbøll
Expert Opinion on Emerging Drugs|September 13, 2011
Emerging GLP-1 receptor agonistsAsger Lund, Filip K Knop, Tina Vilsbøll
Mayo Clinic Proceedings|January 9, 2018
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 DiabetesSofie Hædersdal, Asger Lund, Filip K Knop, et al.
Nature Reviews. Endocrinology|May 6, 2018
Glucagon-like peptide 1 in health and diseaseAndreas Andersen, Asger Lund, Filip K Knop, et al.
Current Diabetes Reports|October 27, 2014
Glucagon and type 2 diabetes: the return of the alpha cellAsger Lund, Jonatan I Bagger, Mikkel Christensen, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 10, 2011
The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetesAsger Lund, Tina Vilsbøll, Jonatan I Bagger, et al.
Medical Hypotheses|November 9, 2015
Involvement of steatosis-induced glucagon resistance in hyperglucagonaemiaMalte P Suppli, Asger Lund, Jonatan I Bagger, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Danish Medical Journal|April 8, 2017
On the role of the gut in diabetic hyperglucagonaemiaAsger Lund
Diabetes Research and Clinical Practice|June 27, 2018
Extrapancreatic glucagon: Present statusAsger Lund, Filip K Knop
Current Medical Research and Opinion|April 3, 2012
Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylureaAsger Lund, Filip K Knop
European Journal of Internal Medicine|April 4, 2014
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similaritiesAsger Lund, Filip K Knop, Tina Vilsbøll
Expert Opinion on Emerging Drugs|September 13, 2011
Emerging GLP-1 receptor agonistsAsger Lund, Filip K Knop, Tina Vilsbøll
Mayo Clinic Proceedings|January 9, 2018
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 DiabetesSofie Hædersdal, Asger Lund, Filip K Knop, et al.
Nature Reviews. Endocrinology|May 6, 2018
Glucagon-like peptide 1 in health and diseaseAndreas Andersen, Asger Lund, Filip K Knop, et al.
Current Diabetes Reports|October 27, 2014
Glucagon and type 2 diabetes: the return of the alpha cellAsger Lund, Jonatan I Bagger, Mikkel Christensen, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 10, 2011
The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetesAsger Lund, Tina Vilsbøll, Jonatan I Bagger, et al.
Medical Hypotheses|November 9, 2015
Involvement of steatosis-induced glucagon resistance in hyperglucagonaemiaMalte P Suppli, Asger Lund, Jonatan I Bagger, et al.
Pageof 6